RCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at ASCO

HUTCHMED (China)Announcement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260522:nRSV3434Fa&default-theme=true

RNS Number : 3434F  Hutchmed (China) Limited  22 May 2026

Press Release

 

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

Hong Kong, Shanghai & Florham Park, NJ - Friday, May 22, 2026: HUTCHMED
(China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that
new and updated data from several studies of compounds discovered by HUTCHMED
will be presented at the American Society of Clinical Oncology ("ASCO") Annual
Meeting taking place from May 29 to June 2, 2026 in Chicago, USA.

 

Results from the pivotal Phase II registration study of savolitinib in gastric
cancer or gastroesophageal junction adenocarcinoma patients with MET
amplification in China will be presented during a rapid oral session. The
study met its primary endpoint of objective response rate ("ORR") per RECIST
1.1, as assessed by the Independent Review Committee ("IRC"). As of the data
cut-off of October 8, 2025, the IRC-assessed ORR was 32.3% (95%CI: 21.2%,
45.1%), exceeding the pre-specified efficacy threshold. Secondary endpoints
included the IRC-assessed disease control rate (DCR) of 63.1%, median time to
response (TTR) of 1.4 months, median duration of response (DoR) of 9.7
(95%CI: 3.7, 18.5) months, and median progression-free survival (PFS) of 4.0
(95%CI: 2.6, 5.0) months, respectively. The data supported the New Drug
Application (NDA) submission to the China National Medical Products
Administration (NMPA), which was accepted and granted priority review in
December 2025.

 

Additionally, further analyses of the fruquintinib's FRESCO, FRESCO-2,
FRUSICA-1 and FRUSICA-2 studies, as well as investigator-initiated studies of
fruquintinib and surufatinib spanning across a diverse range of potential
tumor indications will be presented.

 

Details of the presentations, including links to available abstracts, are as
follows:

 

 Abstract title                                                                   Presenter / Lead Author                  Presentation details
 SPONSORED STUDIES
 A phase 2 pivotal study of savolitinib in patients with MET-amplified gastric    Zhi Peng, Beijing, China                 4011
 cancer or gastroesophageal junction adenocarcinomas                                                                       Rapid Oral Abstract Session: Gastrointestinal Cancer - Gastroesophageal,
                                                                                                                           Pancreatic, and Hepatobiliary
                                                                                                                           Monday, June 1, 2026 1:15 PM CDT
 Tumor shrinkage and depth of response with fruquintinib in patients with         Elena Elez, Barcelona, Spain             3555
 metastatic colorectal cancer: Results from FRESCO and FRESCO-2                                                            Poster Session: Gastrointestinal Cancer - Colorectal and Anal
 Efficacy of fruquintinib plus sintilimab versus axitinib or everolimus by        Kaiwei Yang, Beijing, China              4531
 scores of IMDC risk factors and PD-L1 expression at baseline in previously
Poster Session: Genitourinary Cancer
 treated advanced renal cell carcinoma: A subgroup analysis of FRUSICA-2 study
- Kidney and Bladder
 Efficacy with fruquintinib plus sintilimab versus axitinib or everolimus in      Yuanyuan Qu, Shanghai, China             4533
 advanced renal cell carcinoma: A post-hoc analysis from FRUSICA-2 trial by
Poster Session: Genitourinary Cancer
 baseline tumor burden
- Kidney and Bladder
 Association of Palmar-plantar erythrodysesthesia syndrome (PPES),                Xiaotian Han, Shanghai, China            e17612
 hypothyroidism and clinical outcome in previously treated endometrial cancer
Publication Only: Gynecologic Cancer
 (EMC) with pMMR status: A subgroup analysis of FRUSICA-1

 INVESTIGATOR-INITIATED STUDIES
 Efficacy and safety of fruquintinib combined with chemotherapy versus            Jianmin Xu, Shanghai, China              LBA3563
 bevacizumab combined with chemotherapy as second-line treatment for metastatic                                            Poster Session: Gastrointestinal Cancer - Colorectal and Anal
 colorectal cancer: A prospective, multicenter, randomized controlled trial
 CONCEPT (combination of cetuximab plus fruquintinib treatment ±                  Yue Liu, Hangzhou, China                 TPS3680
 immunotherapy): A multicenter, randomized, open-label phase II trial in
Poster Session: Gastrointestinal Cancer - Colorectal and Anal
 first-line pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer
 Fruquintinib in combination with tislelizumab vs trifluridine/tipiracil and      Joseph Tintelnot, Hamburg, Germany       TPS3684
 bevacizumab in MSS mCRC without active liver metastases: The IKF-080/QUINTIS
Poster Session: Gastrointestinal Cancer - Colorectal and Anal
 trial
 A phase 2 study of fruquintinib combined with sintilimab and chidamide in        Chang Wang, Changchun, China             2631
 refractory MSS metastatic colorectal cancer: Preliminary efficacy and safety
Poster Session: Developmental Therapeutics - Immunotherapy
 Fruquintinib plus FOLFIRI or mFOLFOX6 as second-line therapy for patients with   Yun Xu, Shanghai, China                  3528
 RAS-mutant metastatic colorectal cancer (mCRC): A phase II, multicenter,
Poster Session: Gastrointestinal Cancer - Colorectal and Anal
 open-label study
 A randomized phase II trial of fruquintinib plus capecitabine versus             Wenhua Li, Shanghai, China               3534
 capecitabine alone as maintenance therapy following first-line chemotherapy in
Poster Session: Gastrointestinal Cancer - Colorectal and Anal
 metastatic colorectal cancer (mCRC)
 A phase II trial of fruquintinib combined with cadonilimab in refractory         Mengzhou Guo, Shanghai, China            3552
 MSS/pMMR colorectal cancer with pulmonary metastases
Poster Session: Gastrointestinal Cancer - Colorectal and Anal
 Biomarker-driven assessment of immunochemotherapy with or without fruquintinib   Xiaodong Zhu, Shanghai, China            4063
 as first-line treatment for advanced gastric/GEJ adenocarcinoma: Initial
Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and
 clinical results and subgroup analysis from the MGC-FLORA study                                                           Hepatobiliary
 Phase II study of utidelone plus fruquintinib for the treatment of               Hao Wen, Shanghai, China                 5579
 platinum-resistant recurrent ovarian cancer (FRUTD trial)
Poster Session: Gynecologic Cancer
 Fruquintinib alternating with bevacizumab plus capecitabine as maintenance       Wangjun Liao, Guangzhou, China           e15539
 therapy after first-line treatment in metastatic colorectal cancer (mCRC): A
Publication Only: Gastrointestinal Cancer - Colorectal and Anal
 multicenter, open-label, phase II study
 Intermittent fruquintinib plus trifluridine/tipiracil in refractory metastatic   Yifu He/ Jiayu Niu, Hefei, China         e15560
 colorectal cancer (mCRC): A single-center, single-arm phase II study
Publication Only: Gastrointestinal Cancer - Colorectal and Anal
 Phase I study of liposomal irinotecan plus fruquintinib as third- or             Qian Li, Nanning, China                  e15571
 later-line therapy for metastatic colorectal cancer
Publication Only: Gastrointestinal Cancer - Colorectal and Anal
 Chidamide combined with serplulimab and regorafenib or fruquintinib as           Wei Li, Suzhou, China                    e15583
 third-line therapy for advanced colorectal cancer (C-ooperate/SCOG-C001): A
Publication Only: Gastrointestinal Cancer - Colorectal and Anal
 single-arm, exploratory, multicenter, phase 2 trial
 Real-world use of fruquintinib in refractory metastatic colorectal cancer in     Vasu Bansal, Kansas City, US             e15713
 the United States
Publication Only: Gastrointestinal Cancer - Colorectal and Anal
 Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment   Beibei Chen, Zhengzhou, China            e16033
 for advanced gastric/gastroesophageal junction adenocarcinoma: A single-arm,
Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and
 open-label, multicenter phase Ib/II study (FUNCTION)                                                                      Hepatobiliary
 Fruquintinib in combination with camrelizumab, paclitaxel liposome, and          Yanhong Gu, Nanjing, China               e16070
 nedaplatin as first-line treatment for advanced esophageal squamous cell
Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and
 carcinoma (ESCC): Updated results from a single-arm, phase II study                                                       Hepatobiliary
 Updated results of surufatinib combined with gemcitabine and cisplatin and       Xuetao Shi/ Jingtao Zhong, Jinan, China  4136
 immune checkpoint inhibitor (ICI) for unresectable locally advanced or
Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and
 metastatic intrahepatic cholangiocarcinoma                                                                                Hepatobiliary
 Surufatinib plus KN046 and chemotherapy as first-line treatment for advanced     Wenquan Wang, Shanghai, China            4198
 pancreatic ductal adenocarcinoma: Updated results and biomarker analysis from
Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and
 a phase 1b/2 trial                                                                                                        Hepatobiliary
 Surufatinib combined with toripalimab for the treatment of recurrent ovarian     Huijuan Yang, Shanghai, China            5586
 clear cell carcinoma: Update of a prospective single center, single-arm phase
Poster Session: Gynecologic Cancer
 II clinical trial
 Surufatinib for advanced or metastatic chemotherapy-refractory thymic            Bei Xu, Shanghai, China                  8119
 epithelial tumor: A single-arm, single-center, phase II study
Poster Session: Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other
                                                                                                                           Thoracic Cancers
 Surufatinib combined with anti-PD-1/PD-L1 antibody in the second line or         Fuxiang Zhou, Wuhan, China               e16172
 monotherapy in third line treatment of advanced hepatocellular carcinoma: A
Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and
 single-arm, open-label, multi-center phase II study                                                                       Hepatobiliary
 Efficacy and safety of surufatinib combined with immune checkpoint inhibitors    Shasha Fan, Changsha, China              e16222
 plus chemotherapy in patients with biliary tract cancers: A real-world study
Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and
                                                                                                                           Hepatobiliary
 Osimertinib plus savolitinib in osimertinib-resistant non-small-cell lung        Xiang Han, Qingdao, China                e20079
 cancer with low level gene copy number MET: A multi-center, open-label, and
Publication Only: Lung Cancer -
 phase 2 study
Non-Small Cell Local-Regional/

Small Cell/Other Thoracic Cancers

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception it has
focused on bringing drug candidates from in-house discovery to patients around
the world, with its first three medicines marketed in China, the first of
which is also approved around the world including in the US, Europe and Japan.
For more information, please visit: www.hutch‑med.com or follow us on
LinkedIn.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the US Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED's current
expectations regarding future events, including but not limited to its
expectations regarding the therapeutic potential of fruquintinib, savolitinib
and surufatinib, the further clinical development for fruquintinib,
savolitinib and surufatinib, its expectations as to whether any studies on
fruquintinib, savolitinib and surufatinib would meet their primary or
secondary endpoints, and its expectations as to the timing of the completion
and the release of results from such studies. Such risks and uncertainties
include, among other things, assumptions regarding enrollment rates and the
timing and availability of subjects meeting a study's inclusion and exclusion
criteria; changes to clinical protocols or regulatory requirements; unexpected
adverse events or safety issues; the ability of fruquintinib, savolitinib and
surufatinib, including as combination therapies, to meet the primary or
secondary endpoint of a study, to obtain regulatory approval in different
jurisdictions and to gain commercial acceptance after obtaining regulatory
approval; the potential markets of fruquintinib, savolitinib and surufatinib
for a targeted indication, and the sufficiency of funding. In addition, as
certain studies rely on the use of other drug products as combination
therapeutics, such risks and uncertainties include assumptions regarding their
safety, efficacy, supply and continued regulatory approval. Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. For
further discussion of these and other risks, see HUTCHMED's filings with the
US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited
and on AIM. HUTCHMED undertakes no obligation to update or revise the
information contained in this press release, whether as a result of new
information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be
available in all countries, or may be available under different trademarks,
for different indications, in different dosages, or in different strengths.
Nothing contained herein should be considered a solicitation, promotion or
advertisement for any prescription drugs including the ones under development.

 

CONTACTS
 Investor Enquiries                             +852 2121 8200 / ir@hutch-med.com

 Media Enquiries
 FTI Consulting -                               +44 20 3727 1030 / HUTCHMED@fticonsulting.com
    Ben Atwell / Tim Stamper                       +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
 Brunswick - Zhou Yi                            +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

 Panmure Liberum                                Nominated Advisor and Joint Broker
 Atholl Tweedie / Emma Earl / Rupert Dearden    +44 20 7886 2500

 Cavendish                                      Joint Broker
 Geoff Nash / Nigel Birks                       +44 20 7220 0500

 Deutsche Numis                                 Joint Broker
 Duncan Monteith / Ramin Naji                   +44 20 7545 8000

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABUGDUGUDDGLB



            Copyright 2019 Regulatory News Service, all rights reserved